OBJECTIVE： To investigate the situation of drug use in CHD inpatients， and to provide reference for relevant decision-making. METHODS： Medical records of CHD patients were collected by medical insurance system from 8 medical institutions of Mianyang area during Jan. 2014-Dec. 2016. Each 200 medical records were collected from each medical institution and then analyzed statistically by EXCEL 2007， ACCESS 2007， SPSS 19.0 software in respects of patient’s gender and age， drug amount， drug type， drug combination. RESULTS： A total of 1 600 patients were included， involving 983 male and 707 female with average age of （73.9±10.2） years old. Drug cost ratio was 35.2％ of total hospitalization cost； CHD treatment drugs accounted for 72.4％ of the total drug cost. Among adjuvant therapy drugs， the cost of Chinese patent medicines and 4 chemical medicines containing TCM extracted component which could improve circulation accounted for 37.8％ of cardiovascular drug cost. Among main therapy drugs， the utilization rate of lipid-modulating drugs was 80.8％， and that of ACEI and ARB was 46.9％. The patients receiving antiplatelet drug combined with PPI accounted for 54.9％ of the patients receiving antiplatelet drug. Fourteen patients were treated with short-acting Nifedipine tablets. Forty-two patients were treated with clopidogrel and omeprazole. CONCLUSIONS： The utilization of adjuvant therapy drugs such as L-carnitine show high cost ratio. ACEI or ARB， lipid-lowering drugs take up low proportion in CHD patients. The use of short-acting Calcium channel blocker （CCB） and dipyridamole are unreasonable. The indication control of PPIs is lax and the abuse of Chinese patent medicine is obvious.